INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer’s readout. Lead asset XPro1595’s mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback